To combine the scientific breakthrough of CB1 with innovative drug development to provide new effective and safe treatments for brain diseases with unmet medical needs.
Aelis Farma announces the recruitment of the first patient for the phase 1/2 clinical trial of its drug candidate AEF0217 for the treatment of cognitive diso...
December 2022
+
Aelis Farma announces positive results from its safety trials in healthy volunteers and the authorization to start the first trial in people with Down syndro...